【ChiCTR2600131879】Effects of Brief Behavioural Treatment for Insomnia in Older Adults: A Randomised Controlled Trial
ChiCTR2600131879
尚未开始
/
/
/
2026-09-07
/
/
Insomnia
Effects of Brief Behavioural Treatment for Insomnia in Older Adults: A Randomised Controlled Trial
Effects of Brief Behavioural Treatment for Insomnia in Older Adults: A Randomised Controlled Trial
1. To determine whether older adults receiving Brief Behavioural Treatment for Insomnia (BBTI) demonstrate greater reductions in insomnia severity than those in the control group immediately post-intervention and at 3-month follow-up. 2. To determine whether older adults receiving BBTI demonstrate greater reductions in depressive symptoms than those in the control group immediately post-intervention and at 3-month follow-up. 3. To generate local evidence on the effectiveness of BBTI in improving insomnia severity and depressive symptoms among Chinese older adults in Hong Kong.
随机平行对照
其它
Participants will be randomly allocated to either the BBTI intervention group or the sleep hygiene control group in a 1:1 ratio. Random assignment will follow a computer-generated allocation sequence using permuted block randomization with a block size of four.
The study is assessor-blinded
The trial is implemented entirely using existing institutional and service resources from Castle Peak Hospital (Hospital Authority) in collaboration with the School of Nursing and Health Sciences, Hong Kong Metropolitan University (which provides academic support and project coordination).
/
46
/
2026-09-09
2027-12-31
/
1. Aged 65 years or older 2. Difficulty initiating sleep and/or maintaining sleep, indicated by a sleep onset latency and/or wake after sleep onset ≥30 minutes, together with a total sleep time <=6.5 hours per night; 3. Symptoms occurring on more than three nights per week for longer than three months; 4. Sleep disturbance and/or associated daytime fatigue causing clinically significant distress or impairment in social, occupational, or other important areas of functioning. 1. Aged 65 years or older2. Difficulty initiating sleep and/or maintaining sleep, indicated by a sleep onset latency and/or wake after sleep onset ≥30 minutes, together with a total sleep time <=6.5 hours per night;3. Symptoms occurring on more than three nights per week for longer than three months;4. Sleep disturbance and/or associated daytime fatigue causing clinically significant distress or impairment in social, occupational, or other important areas of functioning.;
请登录查看1. Have a progressive or unstable physical illness (e.g., cancer, acute pain); 2. Having mild cognitive impairment, as indicated by Montreal Cognitive Assessment 5-Minute Protocol Hong Kong Version (HK-MoCA 5-Min Protocol) or a known neurodegenerative disorder (e.g., dementia); 3. Major psychiatric comorbidities, including a lifetime diagnosis of psychotic or bipolar disorder, more than two lifetime episodes of major depressive disorder, or an untreated current episode of major depressive disorder; 4. Evidence of other sleep disorders, including sleep apnea (apnea–hypopnea index >15), restless legs syndrome or periodic limb movements with arousal (>15 events/hour), or circadian rhythm sleep–wake disorders (e.g., delayed or advanced sleep phase); 5. Currently misuse alcohol or other substances; 6. Work night shifts and are unable to discontinue shift work during the study period; 7. Are unable to attend in-person sessions; 8. are unable to communicate in Chinese.;
请登录查看Castle Peak Hospital, Hospital Authorit
/
Castle Peak Hospital, Hospital Authorit的其他临床试验
Castle Peak Hospital的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示:#脐带间充质干细胞(#hUC-MSCs)
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点,索弗度肽(survodutide)成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构:国家卫生健康委办公厅、 2026-11-10
-
颁布机构:国家卫健委(原国家卫计委) 2026-11-10
-
颁布机构:国家药品审评中心(CDE) 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-04

